Search

Search Funnelback University

Search powered by Funnelback
10 results 20 results 50 results
Relevance Date (Newest first) Date (Oldest first) Title (A-Z) Title (Z-A) Distance URL (A-Z) URL (Z-A) Shuffle
Did you mean economiespast |u:www.enterprise.cam.ac.uk?
Your query has been expanded to Economics test |u:www.enterprize.cam.ac.uk.  Search for Economics test |u:www.enterprise.cam.ac.uk instead.
31 - 38 of 38 search results for Economics test |u:www.enterprise.cam.ac.uk or Economics test |u:www.enterprize.cam.ac.uk where 2 match all words and 36 match some words.

  1. Results that match 1 of 2 words

  2. Plant protein pioneer, Xampla, raises £2m funding – Cambridge…

    https://www.enterprise.cam.ac.uk/news/xampla-breakthrough-plant-protein-solution-for-hidden-plastics-receives-funding-boost/
    Thumbnail for Plant protein pioneer, Xampla, raises £2m funding – Cambridge Enterprise 23 Feb 2023: The scale of the potential economic impact of the EU’s proposed restriction can be seen in data submitted by the industry to the ECHA’s stakeholder workshop.

  3. Horizon Discovery, DefiniGEN collaborate on iPS-based cell lines –…

    https://www.enterprise.cam.ac.uk/news/horizon-discovery-definigen-announce-collaboration-to-develop-gene-engineered-ips-based-cell-lines/
    Thumbnail for Horizon Discovery, DefiniGEN collaborate on iPS-based cell lines – Cambridge Enterprise 22 Feb 2023: These next-generation iPS cell products will help to improve the efficiency and economics of drug development, and enable the underlying mechanisms of disease to be elucidated in a manner that ... Dr Marcus Yeo, CEO, DefiniGEN, commented: “These

  4. CellCentric raises $26m to take first-in-class p300/CBP inhibitor…

    https://www.enterprise.cam.ac.uk/news/cellcentric-raises-26-million-to-take-first-in-class-p300cbp-inhibitor-into-the-clinic/
    Thumbnail for CellCentric raises $26m to take first-in-class p300/CBP inhibitor into the clinic – Cambridge Enterprise 22 Feb 2023: The funds will be used to test the novel p300/CBP inhibitor in late stage, treatment-resistant prostate cancer (up to Phase IIb).

  5. University of Cambridge breaks its early stage investment record for…

    https://www.enterprise.cam.ac.uk/news/university-of-cambridge-breaks-its-early-stage-investment-record-for-third-consecutive-year/
    Thumbnail for University of Cambridge breaks its early stage investment record for third consecutive year – Cambridge Enterprise 22 Feb 2023: This was the fourth year of operation for the Enterprise Fund, which was announced as part of the SEIS programme in the government’s 2012 budget, established to stimulate economic growth.

  6. University of Cambridge breaks its early stage investment record for…

    https://www.enterprise.cam.ac.uk/news/university-of-cambridge-breaks-its-early-stage-investment-record-for-the-fourth-consecutive-year/
    Thumbnail for University of Cambridge breaks its early stage investment record for the fourth consecutive year – Cambridge Enterprise 22 Feb 2023: This was the fourth year of operation for the Enterprise Fund, which was announced as part of the SEIS programme in the government’s 2012 budget, established to stimulate economic growth.

  7. Cambridge joins consortium to launch £40 million Apollo fund to drive …

    https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-joins-consortium-world-leading-uk-universities-global-pharmaceutical-companies-launch-40-million-fund-drive-therapeutic-innovation/
    Thumbnail for Cambridge joins consortium to launch £40 million Apollo fund to drive therapeutic innovation – Cambridge Enterprise 22 Feb 2023: valuable proposition for any academic or company that wants to see early stage ground breaking therapeutic technology progress to the clinic for patient benefit and economic return. ... for patient benefit and economic return.”.

  8. Portfolio company Mission Therapeutics awarded research grant from…

    https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-portfolio-company-mission-therapeutics-awarded-research-grant-from-the-michael-j-fox-foundation/
    Thumbnail for Portfolio company Mission Therapeutics awarded research grant from the Michael J Fox Foundation – Cambridge Enterprise 22 Feb 2023: The objective of the research collaboration with Prof Wade-Martins is to test Mission’s potent and selective USP30 inhibitors in a range of disease models—induced Pluripotent Stem Cells ... There is no objective test, or biomarker, for Parkinson’s

  9. New agreement with Cambridge spin-out PredictImmune lets SLE join…

    https://www.enterprise.cam.ac.uk/news/new-agreement-with-university-spin-out-predictimmune-allows-product-pipeline-to-include-systemic-lupus-erythematosus/
    Thumbnail for New agreement with Cambridge spin-out PredictImmune lets SLE join pipeline – Cambridge Enterprise 22 Feb 2023: As with IBD, patients with SLE can present with a variable disease course, and it is this variability that makes it an ideal choice for the development of a prognostic test

Refine your results

clear all

Date

Search history

Recently clicked results

Recently clicked results

Your click history is empty.

Recent searches

Recent searches

Your search history is empty.